T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes

Patients with B-cell malignancies receiving CD19-targeted chimeric antigen receptor (CAR) T-cell therapy may experience treatment failure due to various mechanisms. One significant factor is the host’s immune response against the CAR-T product, mainly triggered by the immunogenicity of non-human seq...

Description complète

Détails bibliographiques

Auteurs principaux:	Manel Juan, Alvaro Urbano-Ispizua, Eddie James, William W Kwok, Susana Rives, Valentín Ortiz-Maldonado, Anna Alonso-Saladrigues, Julio Delgado, Europa Azucena González-Navarro, Ariadna Bartoló-Ibars, Andrea Aran, Alexandra M Johansson, Nela Klein-González
Format:	Artigo
Langue:	Inglês
Publié:	BMJ Publishing Group 2025-09-01
Collection:	Journal for ImmunoTherapy of Cancer
Accès en ligne:	https://jitc.bmj.com/content/13/9/e010792.full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!